Hyperthermia enhances the efficacy of PD-1 inhibitor plus chemotherapy in PD-L1 CPS-negative advanced gastric cancer - Scorecard - MDSpire

Hyperthermia enhances the efficacy of PD-1 inhibitor plus chemotherapy in PD-L1 CPS-negative advanced gastric cancer

  • By

  • Weihang Li

  • Xin Sun

  • Ping Li

  • Ting Wang

  • Panling Xu

  • May 13, 2026

  • 0 min

Share

Clinical Scorecard: The Role of Hyperthermia in Improving Outcomes of PD-1 Inhibitor and Chemotherapy for Advanced Gastric Cancer with Negative PD-L1 CPS

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingOncology Center of the First Affiliated Hospital of Anhui Medical University (January 2021 - June 2022).

Key Highlights

  • Add specific p-values for all claims regarding statistical significance.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Include recommendations for follow-up care and long-term monitoring.

      Risks

        Patient & Prescribing Data

        72 patients with advanced gastric cancer, PD-L1 CPS-negative.

        Combination therapy with hyperthermia shows promise in enhancing treatment outcomes.

        Clinical Best Practices

        • assess_patient_eligibility

        Related Resources & Content

        Original Source(s)

        Hyperthermia enhances the efficacy of PD-1 inhibitor plus chemotherapy in PD-L1 CPS-negative advanced gastric cancer

        • by Weihang Li, Xin Sun, Ping Li, Ting Wang, Panling Xu

        • May 13, 2026

        Related Content

        Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

        Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

        Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases